Login | Register

Synribo (Omacetaxine Mepesuccinate) For Myelogenous Leukemia, Approved By FDA

Synribo (omacetaxine mepesuccinate) has been approved by the FDA (US Food and Drug Administration) for the treatment of chronic myelogenous leukemia (CML) in adult patients. Chronic myelogenous leukemia is also known as chronic myeloid leukemia. Approximately 5,430 are expected to be diagnosed with CML, a blood and bone marrow disease, in 2012, says the NIH (National Institutes of Health)...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *